Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4549153 | 0.89 | BACE1 (0.49) | BACE1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7535325 | 0.89 | BACE1 (0.61) | BACE1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7541964 | 0.87 | BACE1 (0.43) | BACE1 | |
| SCHEMBL4549165 | 0.85 | BACE1 (0.45) | BACE1CTSDCYP3A4 | |
| SCHEMBL4549145 | 0.85 | BACE1 (0.64) | BACE1CTSD | |
| SCHEMBL8191277 | 0.84 | BACE1 (0.41) | BACE1 | |
| SCHEMBL7539823 | 0.84 | BACE1 (0.43) | BACE1CYP3A4 | |
| SCHEMBL7599897 | 0.84 | BACE1 (0.43) | BACE1 | |
| SCHEMBL7534807 | 0.84 | BACE1 (0.43) | BACE1CTSDCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7573583 | 0.84 | BACE1 (0.43) | BACE1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2644600-B1 | Heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME (US) | 2017-01-11 | — | — | EP | disclosed |
| US-8629155-B2 | Aspartyl protease inhibitors | MERCK SHARP & DOHME, CORP. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629155-B2 | Aspartyl protease inhibitors | MERCK SHARP & DOHME, CORP. (US) | 2014-01-14 | — | — | US | disclosed |
| EP-2644600-A1 | Heterocyclic aspartyl protease inhibitors | Merck Sharp & Dohme Corp. (US) | 2013-10-02 | — | — | EP | disclosed |
| US-20120232064-A1 | ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232064-A1 | ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2012-09-13 | — | — | US | disclosed |
| US-8168641-B2 | Aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168641-B2 | Aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232064-A1 | ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, BACE1 | BACE1 3/4885CTSD 144/4885CYP3A4 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.